Empowering dentists to reduce opioid prescriptions to young people

授权牙医减少向年轻人开阿片类药物处方

基本信息

  • 批准号:
    10620388
  • 负责人:
  • 金额:
    $ 58.02万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-01-01 至 2023-12-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Dentists are the leading prescriber of opioids to adolescents and young adults (AYAs), even though opioid use after tooth extraction is not associated with improved pain control or satisfaction. In AYAs, an opioid prescription after a dental procedure increases the risk of opioid misuse, use disorder, and overdose. The long-term goal of this project is to develop a framework to reduce opioid prescriptions to AYAs for treatment of acute dental pain. The objective of this proposal is to establish the effectiveness of a multicomponent intervention at reducing dental opioid prescription rates after tooth extraction in AYAs. Our central hypothesis is that a multicomponent intervention is required to produce significant reductions in post-extraction opioid prescriptions to AYAs. The rationale underlying this proposal is that a multicomponent intervention will address provider knowledge, motivation, and choice architecture better than a single-component strategy; will engage and educate patients; and will provide a physical item for distribution instead of an opioid prescription. We will test this hypothesis by pursuing four specific aims: in the UG3 period, 1) complete requisite preliminary work to test a new approach to manage acute pain following dental treatment, and in the UH3 period: 1) establish effectiveness of a novel educational and drug-dispensing approach using academic detailing, patient education, and blister-packaged non-opioid analgesics to reduce opioid prescriptions following tooth extraction among AYAs; 2) examine key implementation outcomes of the intervention designed to modify dental professional decision-making behaviors; and 3) assess patient-reported pain management, analgesic use, and drug disposal after tooth extraction. To accomplish these aims, we propose a stepped wedge cluster randomized trial of community and academic clinics across Kentucky using an innovative intervention of one-on-one provider education plus provider distribution of patient education materials and standardized blister packs containing acetaminophen and ibuprofen. This study will be conducted across at least 10 of the largest oral surgery practices in Kentucky, enrolling at least 27 providers expected to perform tooth extractions on over 40,000 AYAs. We will assess effectiveness using a primary endpoint of the patient-level binary indicator of being prescribed an opioid. Secondary endpoints include intervention acceptability, appropriateness, feasibility, and fidelity (UH3 aim 2); and patient-reported pain, pain interference, analgesic use, and drug disposal (UH3 aim 3). The proposed research is significant because it will provide a framework for wide-scale implementation of interventions to modify dental decision-making behaviors towards evidence-based recommendations for acute pain management, resulting in a reduction in opioid prescription rates after tooth extraction. The expected outcome is a framework to implement effective interventions to reduce dental opioid prescribing to AYAs. The results will have a positive impact immediately because they will limit unnecessary opioid exposure, and long-term because they will help dentistry build a framework for reducing the impact of substance use disorders across the United States.
抽象的 牙医是青少年和年轻人(AYAS)的阿片类药物的领先处方者,即使阿片类药物使用 拔牙后与改善疼痛控制或满意度无关。在Ayas,阿片类药物处方 经过牙科手术,增加了阿片类药物滥用,使用障碍和过量的风险。长期目标 该项目旨在开发一个框架,以减少AYA的阿片类药物处方,以治疗急性牙齿疼痛。 该提案的目的是确定多组分干预的有效性 AYA中拔牙后的牙科阿片类药物处方率。我们的中心假设是多组分 需要干预才能大幅减少对AYA的萃取后阿片类药物处方。这 该提案的基本原理是多组分干预将解决提供商知识, 动机和选择体系结构比单一组成策略更好;将吸引和教育患者; 并将提供一个物理物品用于分发而不是阿片类药物处方。我们将通过 追求四个具体目标:在UG3期间,1)完成必要的初步工作以测试一种新方法 在牙科治疗后以及在UH3期间处理急性疼痛:1)建立新颖的有效性 使用学术细节,患者教育和水泡包装的教育和药物分解方法 非阿片类镇痛药可减少AYA拔牙后的阿片类药物处方; 2)检查密钥 旨在修改牙科专业决策行为的干预措施的实施结果; 3)评估拔牙后患者报告的疼痛管理,镇痛药和药物处置。到 完成这些目标,我们建议对社区和学术诊所的阶梯楔形集群随机试验 在整个肯塔基州,都使用一对一提供商教育以及提供商分布的创新干预措施 患者教育材料和含有对乙酰氨基酚和布洛芬的标准化水泡包。这项研究 将在肯塔基州至少10个最大的口腔外科手术实践中进行,至少27 预计提供者将对超过40,000个AYA进行牙齿拔牙。我们将使用 处方阿片类药物的患者级二进制指标的主要终点。次要端点 包括干预可接受性,适当性,可行性和保真度(UH3 AIM 2);和患者报告的疼痛, 疼痛干扰,镇痛和药物处理(UH3 AIM 3)。拟议的研究很重要,因为 它将为大规模实施干预措施提供一个框架,以修改牙科决策 朝着基于证据的急性疼痛管理建议的行为,导致减少 拔牙后阿片类药物处方率。预期的结果是实施有效的框架 减少对AYA的牙科药物处方的干预措施。结果将立即产生积极影响 因为它们将限制不必要的阿片类药物暴露,并且长期是因为它们将帮助牙科建造一个 减少美国物质使用障碍影响的框架。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Douglas Oyler其他文献

Douglas Oyler的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Douglas Oyler', 18)}}的其他基金

Understanding the Association between Sublingual Buprenorphine and Oral Health Outcomes
了解舌下含服丁丙诺啡与口腔健康结果之间的关联
  • 批准号:
    10765299
  • 财政年份:
    2023
  • 资助金额:
    $ 58.02万
  • 项目类别:

相似国自然基金

CHAC1通过调控蛋白谷胱甘肽化修饰促进对乙酰氨基酚诱导急性药物性肝损伤的作用和机制研究
  • 批准号:
    82370597
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
OPTN调控对乙酰氨基酚急性肝损伤的分子机制研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    24 万元
  • 项目类别:
    青年科学基金项目
共刺激分子OX40通过调控CD4+T 细胞活化加重对乙酰氨基酚急性肝损伤的机制研究
  • 批准号:
    81900526
  • 批准年份:
    2019
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Senescent hepatocytes mediate reprogramming of immune cells in acute liver failure
衰老肝细胞介导急性肝衰竭中免疫细胞的重编程
  • 批准号:
    10679938
  • 财政年份:
    2023
  • 资助金额:
    $ 58.02万
  • 项目类别:
Novel strategies to accelerate repair of drug-induced hepatotoxicity
加速修复药物引起的肝毒性的新策略
  • 批准号:
    10718314
  • 财政年份:
    2023
  • 资助金额:
    $ 58.02万
  • 项目类别:
Diverging roles of EGFR and MET in acetaminophen-induced acute liver injury
EGFR 和 MET 在对乙酰氨基酚诱导的急性肝损伤中的不同作用
  • 批准号:
    10633557
  • 财政年份:
    2023
  • 资助金额:
    $ 58.02万
  • 项目类别:
The role of liver progenitor cells in liver regeneration
肝祖细胞在肝再生中的作用
  • 批准号:
    10607301
  • 财政年份:
    2023
  • 资助金额:
    $ 58.02万
  • 项目类别:
Novel Treatment for Alcohol-associated Liver Disease
酒精相关性肝病的新疗法
  • 批准号:
    10698605
  • 财政年份:
    2023
  • 资助金额:
    $ 58.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了